Introducing the Recana® Thrombectomy Catheter System

The First Fully Integrated System for the Treatment of Venous In-Stent Restenosis and Native Vessel Obstructions

The Recana® Thrombectomy Catheter System features a fully integrated platform designed to treat venous in-stent restenosis (ISR) and residual thrombotic venous obstructions and occlusions.

I_HeroShot_A_V4
Debulking Catheter
Treat in-stent and native vessel obstructions
I_Basket_30_A_V6
Nitinol Collection Baskets
Lower extremity access & material collection
I_Catheter_Full_V2
Introducer Sheath
Fully integrated system
I_Cath_Hero_Blue_V2
Collection Sheaths
No capital equipment
Debulking Catheter
Treat in-stent and native vessel obstructions
Nitinol Collection Baskets
Lower extremity access & material collection
Introducer Sheath
Fully integrated system
Collection Sheaths
No capital equipment
Logo type 3

View the Recana® System Brochure
View the Recana® System Specifications

Long-Term Complications of Venous Occlusions

Venous In-Stent Restenosis

Venous stenting is commonly used to address obstructions caused by thrombosis, including deep vein thrombosis (DVT), postthrombotic material, and for nonthrombotic iliac vein lesions (NVIL), such as May-Thurner Syndrome that are blockages in the iliac vein not caused by blood clots. 9

In-stent restenosis (ISR) is a frequent complication associated with venous stenting following intervention to remove thrombus and treat residual venous outflow obstruction.

Cases of ISR are challenging to treat and are often limited to balloon angioplasty and stent relining. However, both interventional strategies are often ineffective for maintaining stent patency for patients. 2,3

Long-term Sequela of lower extremity venous thrombosis

Blood clots undergo rapid composition and structural changes from a loose mesh of fibrin and red blood cells to a fibrotic collagenous matrix within three-weeks. 10

Anticoagulation and thrombolytic therapies are more effective in the earlier stages of thrombus development. Patients that experience a deep vein thrombosis may go on to develop a life-long, debilitating condition known as postthrombotic syndrome
(PTS). 6,7

It is estimated that 20%-50% of patients with deep vein thrombosis (DVT) will develop PTS. 6,7 This frequent complication leads to persistent leg swelling, pain, skin discoloration and in the most severe cases, venous leg ulcers. 6,7

Indications For Use:

The Recana Thrombectomy  System is indicated for:
The non-surgical removal of thrombi and emboli from veins.
Injection, infusion, and/or aspiration of contrast media and other fluids into or from a vein.
The Recana Thrombectomy  System is indicated for use in peripheral venous vasculature.   
Refer to IFU for complete Indications for Use, contraindications, warnings and precautions.
 
Caution: Federal (US) law restricts this device to sale by or on the order of a physician
 
Recana is a registered trademark of InterVene Inc. All trademarks are property of their respective owners.